Cancer reports (Hoboken, N.J.) · 2025
A New Radiotranscriptomic Approach to Analyze Combined Sets of T3b Stage-Specific Genes and Radiomic Features in Prostate Cancer.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Qian, Tang Peng, Mo Jiao, Li Qiuyang, Huang Jiahui, Han Xiaoyu, Xu Hao, Liu Xi, Tang Jie
Аннотация
BACKGROUND: Current clinical staging of prostate cancer (PCa) using the tumor-node-metastasis (TNM) system and serum biomarkers remains limited in distinguishing locally advanced (T3b) PCa from organ-confined (T2c) disease.
AIMS: Building on our previous biomarker discovery in differentiating PCa from that of benign prostatic hyperplasia, this study pioneers a radiotranscriptomic model to distinguish T3b stage PCa from T2c stage PCa by integrating contrast-enhanced ultrasound (CEUS) radiomics with stage-specific transcriptomic signatures, addressing a critical knowledge gap in precision staging.
METHODS AND RESULTS: This prospective study was approved by the review board of Chinese PLA General Hospital (S2021-565-01), and all participants provided written informed consent. Transrectal B-mode ultrasound images and contrast-enhanced ultrasound images on two imaging planes were prospectively analyzed in 48 patients with biopsy-confirmed PCa (35 patients with stage T2c and 13 with stage T3b). Textural features were evaluated using microvascular ultrasonography and contrast-enhanced ultrasound. Radiomic data were then retrieved from all modes. An across-the-board investigation of mRNA and miRNA expressions was also performed in the two PCa stages. Six biomarkers (frizzled 4, ribosomal protein S7, ribosomal protein L29, miR-374c, miR-9, and miR-6510) were identified to differentiate T3b stage from T2c stage. The area under the curve (AUC) values of the combined set (AUC = 0.887, 0.956, and 0.996 for random forest, naïve Bayes, and support vector machine, respectively) and radiomic features alone (AUC = 0.921, 0.957, and 0.998, respectively) were found to be more accurate than those of the transcriptomic data alone (AUC = 0.583, 0.716, and 0.898, respectively) or clinical features alone (AUC = 0.585, 0.675, and 0.953, respectively). The PCa gene regulatory network comprised of four miRNAs (miR-148, miR-141, miR-342, and miR-210) may contribute to accelerating tumor progression.
CONCLUSION: We established the new radiotranscriptomic signatures specifically optimized for differentiating T3b stage from T2c stage by decoding stage-specific imaging-genomic crosstalk. This new approach may overcome TNM staging limitations.
AIMS: Building on our previous biomarker discovery in differentiating PCa from that of benign prostatic hyperplasia, this study pioneers a radiotranscriptomic model to distinguish T3b stage PCa from T2c stage PCa by integrating contrast-enhanced ultrasound (CEUS) radiomics with stage-specific transcriptomic signatures, addressing a critical knowledge gap in precision staging.
METHODS AND RESULTS: This prospective study was approved by the review board of Chinese PLA General Hospital (S2021-565-01), and all participants provided written informed consent. Transrectal B-mode ultrasound images and contrast-enhanced ultrasound images on two imaging planes were prospectively analyzed in 48 patients with biopsy-confirmed PCa (35 patients with stage T2c and 13 with stage T3b). Textural features were evaluated using microvascular ultrasonography and contrast-enhanced ultrasound. Radiomic data were then retrieved from all modes. An across-the-board investigation of mRNA and miRNA expressions was also performed in the two PCa stages. Six biomarkers (frizzled 4, ribosomal protein S7, ribosomal protein L29, miR-374c, miR-9, and miR-6510) were identified to differentiate T3b stage from T2c stage. The area under the curve (AUC) values of the combined set (AUC = 0.887, 0.956, and 0.996 for random forest, naïve Bayes, and support vector machine, respectively) and radiomic features alone (AUC = 0.921, 0.957, and 0.998, respectively) were found to be more accurate than those of the transcriptomic data alone (AUC = 0.583, 0.716, and 0.898, respectively) or clinical features alone (AUC = 0.585, 0.675, and 0.953, respectively). The PCa gene regulatory network comprised of four miRNAs (miR-148, miR-141, miR-342, and miR-210) may contribute to accelerating tumor progression.
CONCLUSION: We established the new radiotranscriptomic signatures specifically optimized for differentiating T3b stage from T2c stage by decoding stage-specific imaging-genomic crosstalk. This new approach may overcome TNM staging limitations.